SCHEMBL4851741

SCHEMBL4851741

Nc1ccc(Cl)cc1C(=O)c1cccc(O)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.55
AKR1C4 P17516 1/20 0.54
AKR1C3 P42330 1/20 0.54
AKR1C2 P52895 1/20 0.54
AKR1C1 Q04828 1/20 0.54
FADS1 O60427 1/20 0.50
MAPT P10636 1/20 0.49
HSD17B1 P14061 2/20 0.49
HSD17B2 P37059 2/20 0.49
GFER P55789 1/20 0.49
KMT2A Q03164 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
PARP1 P09874 1/20 0.49
FASN P49327 1/20 0.47
CLK1 P49759 1/20 0.46
DYRK1A Q13627 1/20 0.46
DYRK1B Q9Y463 1/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8080356 0.89 AKR1C4 (0.49) RECQLAKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL6341269 0.88 RECQL (0.60) RECQLFADS1MAPTGFERKMT2A
SCHEMBL6332774 0.83 RECQL (0.58) RECQLFADS1MAPTGFERKMT2A
SCHEMBL31000389 0.83 RECQL (0.67) RECQLMAPTGFERKMT2ASMN1; SMN2
SCHEMBL30484136 0.83 RECQL (0.67) RECQLMAPTGFERKMT2ASMN1; SMN2
SCHEMBL145366 0.83 RECQL (0.67) RECQLMAPTGFERKMT2ASMN1; SMN2
SCHEMBL27860 0.83 MAPT (0.55) RECQLFADS1MAPTGFERKMT2A
SCHEMBL2705329 0.83 RECQL (0.54) RECQLFADS1MAPTGFERKMT2A
SCHEMBL19774168 0.82 MEN1 (0.57) AKR1C4AKR1C3AKR1C2AKR1C1MAPT
Hydrazine SCHEMBL11821861 0.81 RECQL (0.65) RECQLMAPTGFERKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326788-B2 Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-05 US disclosed
US-7326788-B2 Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-05 US disclosed
US-7326788-B2 Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-05 US disclosed
EP-1660087-A2 QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-31 EP disclosed
US-20050049274-A1 Quinolinone derivatives as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-03 US disclosed
WO-2005009967-A2 QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049274-A1 Quinolinone derivatives as inhibitors of c-fms kinase FLT3, ABL1, FES RECQL 838/4885AKR1C4 1918/4885AKR1C3 2404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.